Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689038 · ClinicalTrials.gov registry record · Phase 1
Brain Imaging Study of F17464
A Phase 1 study, sponsored by Pierre Fabre Medicament.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01689038: Completed Phase 1 study, sponsored by Pierre Fabre Medicament.
NCT01689038 is a Phase 1 study that has completed, run by Pierre Fabre Medicament. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689038, a Phase 1 study, has completed, sponsored by Pierre Fabre Medicament.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Assess the binding rate of F17464 to cerebral receptors in healthy volunteers.
Primary Outcome
by brain imaging
Interventions
- DRUG F17464
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01689038 record still lists
NCT01689038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which F17464 is the first listed.
NCT01689038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01689038 about?
NCT01689038 is a clinical study titled "Brain Imaging Study of F17464". Assess the binding rate of F17464 to cerebral receptors in healthy volunteers.
What is the current status of trial NCT01689038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01689038?
The interventions under investigation include: F17464 (DRUG).
Who is sponsoring clinical trial NCT01689038?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01689038's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia